Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer After D2 Gastrectomy (DRAGON-Adjuvant): a Multicenter, Open-label, Phase 3, Randomized, Non-inferiority Study

NCT07366528 is registered in ClinicalTrials.gov with Ruijin Hospital as lead sponsor.

NCT NCT07366528
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07366528 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer After D2 Gastrectomy (DRAGON-Adjuvant): a Multicenter, Open-label, Phase 3, Randomized, Non-inferiority Study
Lead sponsor
Ruijin Hospital
Phase
Phase 3
Overall status
Recruiting
Start date
December 15, 2025
Completion date
October 31, 2030
Enrollment
387 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

adjuvant chemotherapy, docetaxel, gastric cancer (gc), oxaliplatin, stage 3 cancer